阿奇霉素序贯疗法治疗小儿支原体肺炎临床疗效及安全性研究

Study on the clinical efficacy and safety of azithromycin sequential therapy in the treatment of children with mycoplasma pneumonia

目的:探讨阿奇霉素序贯疗法治疗支原体肺炎患儿的临床疗效及安全性。方法:2012年9月-2013年9月收治支原体肺炎患儿100例,随机分为甲组和乙组,各50例,甲组采用阿奇霉素序贯疗法治疗,乙组采用红霉素治疗,对两组的治疗效果以及住院与症状消失时间进行观察,并对比两组的不良反应情况。结果:在治疗总有效率上,甲组98%(49/50),乙组80%(40/50),甲组显著高于乙组(P<0.05);在发热、肺部啰音、咳嗽等消失时间以及住院时间上,甲组要显著低于乙组(P<0.05);在不良反应发生率上,甲组6%(3/50),乙组30%(15/50),甲组显著低于乙组(P<0.05)。结论:针对支原体肺炎患儿,运用阿奇霉素序贯疗法治疗效果显著,不良反应少,安全性高,加快了患儿出院和康复速度,有着重要的临床应用价值。

Objective:To explore the clinical efficacy and safety of azithromycin sequential therapy in the treatment of children with mycoplasma pneumonia.Methods:100 children with mycoplasma pneumonia were selected from September 2012 to September 2013.They were randomly divided into the A group and the B group with 50 cases in each.The A group were treated with azithromycin sequential therapy,and the B group were treated with erythromycin.We observed the effect of treatment and hospitalization and the symptoms disappeared time,and compared the adverse reactions of the two groups.Results:In the total efficiency of treatment,group A was 98%(49/50);group B was 80%(40/50);group A was significantly higher than that in group B(P<0.05).In the fever,pulmonary rales,cough disappeared time and hospitalization time,group A was significantly lower than that of group B(P<0.05).In the incidence of adverse reactions,group A was 6%(3/50);group B was 30%(15/50);group A was significantly lower than that of group B(P<0.05).Conclusion:The clinical efficacy of azithromycin sequential therapy in the treatment of children with mycoplasma pneumonia is significant.The adverse reaction is little,and security is high.It promotes the patient discharged and rehabilitation.So it has important clinical value in use.